Keywords: Pfizer, Lpath, AMD, Ophthalic disorders, iSONEP, ASONEP, Phylogica, Peptide based vaccines

Pfizer signs up to $511 million deal for Lpath’s AMD treatment and $134 million accord for Phylogica’s for peptide-based vaccines

Article | 21 December 2010

Print This

US drug behemoth Pfizer (NYSE: PFE) - which just a couple of weeks ago dumped its chief executive Jeff Kindler ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in